Jaclyn Shaver
Women's Health · Oklahoma City, OKNPI 1376825596
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $715, 6.7 times the $107 reported in 2021.
Across 88 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$328
- Merck$304
- AstraZeneca$295
- GSK$168
- Astellas Pharma US Inc$133
- Myriad Genetic Laboratories, Inc.$104
- plus $560 from 11 others
What the payments were for
- Food & beverage$1,79895%
- Education$945%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 15 | $328 |
| Merck | 15 | $304 |
| AstraZeneca | 13 | $295 |
| GSK | 2 | $168 |
| Astellas Pharma US Inc | 7 | $133 |
| Myriad Genetic Laboratories, Inc. | 6 | $104 |
| Lilly USA, LLC | 7 | $103 |
| Genmab U.S., Inc. | 5 | $83 |
| Seagen Inc. | 4 | $71 |
| Eisai Inc. | 2 | $69 |
| Genentech USA, Inc. | 2 | $49 |
| Tersera Therapeutics LLC | 2 | $44 |
| Stemline Therapeutics Inc. | 2 | $42 |
| Puma Biotechnology, Inc. | 2 | $32 |
| AbbVie | 2 | $31 |
| Incyte Corporation | 1 | $21 |
| Gilead | 1 | $15 |
How this compares
$1,892 in reported general payments places this provider in the 75th percentile of 62 women's health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $12,677 |
| Estradiol | 23 | $1,149 |
| Gabapentin | 33 | $579 |
| Nystatin | 15 | $255 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 13 | $234 |
| Pantoprazole Sodium | 16 | $90 |
| Levothyroxine Sodium | 12 | $56 |
| Prednisone | 15 | $42 |
Paid to pharmacies, not to this prescriber.
Other women's health in Oklahoma City
- Hilary MillerOklahoma City$38K
- Beverly CotnerOklahoma City$4K
- Whitney HunterOklahoma City$3K
- Bethany CookOklahoma City$3K
- Erika RumbleOklahoma City$2K
- Meredith DewitteOklahoma City$2K
- Charnelle DeanOklahoma City$711
- Joyce TowOklahoma City$507
- Maria MeyerOklahoma City$378
- Amanda KenneyOklahoma City$343
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.